Navigation Links
Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program
Date:9/4/2008

pligen established a development program for Friedreich's ataxia. Over the past year, the Company has made significant progress in advancing this program, resulting in the identification of advanced lead compounds with improved potency and specificity. These lead compounds are currently being assessed in pharmacology and toxicology in order to determine if one is suitable for clinical development in Friedreich's ataxia. Repligen is also evaluating this family of compounds for activity in preclinical models of other neurodegenerative diseases including Huntington's disease and spinal muscular atrophy. The MDA grant will partially support the characterization of the lead compounds, including the evaluation of compounds in preclinical models of disease and the completion of the pharmacology and toxicology. The FARA and NAF grant will support the development of new methods to quantitate the impact of drug treatment on frataxin gene expression and frataxin protein in preclinical models and in patients. In further support of this development program, Repligen previously announced receipt of a grant from Go FAR (Friedreich's Ataxia Research), an Italian-based fundraising organization dedicated to raising donations for Friedreich's ataxia research, to develop a biomarker, which may be useful in monitoring the biochemical activity and guiding the dosing of a clinical candidate in patients.

Symptoms of Friedreich's ataxia typically emerge between the ages of 5 and 15 and often progress to severe disability, incapacitation or loss of life in early adulthood. Friedreich's ataxia is caused by a single gene defect that results in inadequate production of the protein frataxin. The protein frataxin appears to be essential for the proper functioning of the mitochondria, the power plant of both neural and muscle cells. Low levels of frataxin lead to degeneration of both the nerves controlling muscle movements in the arms and legs and the nerve tissue in the spinal cord. Approx
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
9. IsoTis Receives FDA Clearance for Accell Family of Products
10. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... According to a new market report published ... Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 ... at USD 161,056.5 million in 2014 and is expected ... to 2020, to reach an estimated value of USD ... is witnessing a significant growth due to the increasing ...
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4
... May 11 /PRNewswire-Asia-FirstCall/ -- China,Baicaotang Medicine Ltd. (OTC Bulletin Board: ... in the, Guangxi Province of China announced today that ... the,Company. , , , ... Mr. Tang Hui Tian , Chairman and CEO of CBT, ...
... of more affordable drugs, vaccines and diagnostics that would ... from a growing number of collaborations between biotech firms ... published Mon. May 10 in the UK journal ... countries, together with colleagues at Canada,s McLaughlin-Rotman Centre for ...
... May 10 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... pharmaceutical company producing over-the-counter drugs in, the People,s Republic of China , ... of $10.1 million for the first quarter,ended March 31, ... ...
Cached Biology Technology:Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 2Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 2Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 3Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 4Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 5Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 6Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms 7China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 2China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 3China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 4China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 5China Sky One Medical Announces Preliminary First Quarter 2010 Results; Reschedules Earnings Conference Call 6
(Date:7/25/2014)... Stowers Institute for Medical Research have identified ... found pheromones crucial to triggering the mating process in ... a male mouse detect pheromones that indicate when a ... him know if the female mouse is ovulating and ... to trigger mating. Stowers, researchers believe mice developed this ...
(Date:7/25/2014)... Florida , July 25, 2014 ... more consumers are turning to digital technology for online ... (OTCBB: NXTD), Google Inc. (NASDAQ: GOOG ), ... (NYSE: V ), Apple Inc. (NASDAQ: ... NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):It takes two to court 2It takes two to court 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... Capabilities for Use in a Wide,Range ... Vision Applications, VILNIUS, Lithuania, Sept. ... provider of high-precision biometric,and object identification ... 2.0 SDK universal object recognition technology ...
... always good to respond maximally when pathogens or disease ... balance immediate and future costs? This is the question ... Tony Williams asked when they examined how a simple ... life-span of individual zebra finches ( Taeniopygia guttata ), ...
... of stripy legs in a camera trap photo snapped in ... from the Wildlife Conservation Society. The legs belong to an ... Republic of Congo,s Virunga National Park, despite over a decade ... the first time this species has been captured on film ...
Cached Biology News:Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 3Individuals vary their immune response according to age, sex and the costs 2Photo reveals rare okapi survived poaching onslaught 2
... Imaging System, Professional Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... digital valve, just 8 mm in width. ... in a single glass-reinforced, PBT (Polybutylene Terephthalate) molded ... width. , Meets a range of pressure requirements ... Satisfies a 0.016 sccm leakage specification (0.2 sccm ...
... FilterMate is a compact, versatile system that ... 96- or 24-well microplates into a solid ... liquid scintillation and gamma counter. The FilterMate ... for applications such as cell proliferation, receptor ...
Biology Products: